Palatin Technologies, Inc. (PTN)

Develops peptide therapeutics for sexual dysfunction disorders and other metabolic diseases.

PTN Stock Quote

Company Report

Palatin Technologies, Inc. is a leading biopharmaceutical company based in Cranbury, New Jersey, dedicated to pioneering targeted receptor-specific therapies for various diseases across the United States. The company's primary focus is on Vyleesi, its flagship product and a melanocortin receptor (MCr) agonist designed for the treatment of hypoactive sexual desire disorder in premenopausal women. Palatin Technologies also advances oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trials, targeting inflammatory bowel diseases.

In addition to its innovative therapies in sexual health and inflammatory conditions, Palatin Technologies is actively developing PL9643, a peptide melanocortin agonist with applications in ocular anti-inflammatory indications like dry eye disease, leveraging its broad-spectrum activity across multiple MCrs including MC1r and MC5r. The company's pipeline further includes PL3994, a peptide mimetic molecule designed with amino acid properties, and L8177, an oral peptide formulation currently in Phase 2 clinical trials for treating ulcerative colitis.

Founded in 1986, Palatin Technologies has established itself as a leader in biopharmaceutical research and development, continually pushing the boundaries of therapeutic innovation. With a commitment to addressing unmet medical needs through targeted therapies, the company remains at the forefront of advancing treatments that enhance patient outcomes and quality of life.

PTN EPS Chart

PTN Revenue Chart

Stock Research

ONB WSBF SNEX POWI PLM CLWT WSBC

PTN Chart

View interactive chart for PTN

PTN Profile

PTN News

Analyst Ratings